The infighting among the nations of Blue Star made Zheng Li realize that it was impossible for them to work together as a whole.

Even in cooperation between China and Russia, there were reservations.

The shortcut Zheng Li had deliberately left on the magic forum was for everyone to collaborate on purchasing technical materials and then share them.

Unexpectedly, even with such a great temptation, the countries of Earth were unable to reach a cooperation agreement.

If cooperation doesn't work, then competition is the only option.

Zheng Li realized that appropriately increasing the intensity of competition and limiting its scope to the field of scientific research would better unleash the potential of Blue Star civilization.

Cooperation seems somewhat ethereal to a Blue Star civilization where war is an eternal theme.

This may be the nature of intelligent life. The sages also fought endlessly in ancient and medieval times.

Li Wanqing said excitedly, "As long as you agree, I'm sure I can convince them. Speaking of biological storage servers, we can put all 1000PB of data on one storage server."

"Subsequent data processing speed can also be greatly increased, which is of great benefit to our processing of brain nerve signals."

The development of brain-computer interface technology for mobile phones has been completed for the mainstream language systems of Earth.

Currently, the research and development of brain-computer interface VR has been mainly completed by Chinese-speaking and English-speaking countries, while other language-speaking countries will begin research and development based on the size of their respective markets.

Zheng Li asked, "What are the test data from the brain-computer interface prosthetic limb test in Jiangcheng?"

Li Wanqing: "The test data is very good. So far, no accidents have occurred due to errors in the recognition of brain nerve signals among all test subjects."

"However, the clinical trial of prosthetics for English-speaking patients has been moved from America to South Africa, and America has not approved our clinical trial application."

"The brain-computer interface prosthesis developed for Chinese language students is ready to apply for production approval."

Kechuang Bio's brain-computer interface technology is non-invasive, so the approval process for its medical devices to go public will be faster.

Zheng thought about it, and realized that a lot of manpower at the R&D centers of Kechuang Bio in Jiangcheng and Suzhou was devoted to the research and development of innovative drugs.

He asked, "What is the progress of innovative drug development? Has any of them started clinical trials?"

It is true that developing innovative drugs is very difficult, but Kechuang Bio has been working on this field since its establishment in 2019.

However, Zheng Li himself has made relatively few contributions in this area. Normally, the development of innovative drugs takes about ten years to yield significant results.

From early research to determining the chemical composition of a new drug, it generally takes 3 to 6 years, while preclinical research takes 1 to 2 years.

After this long process, there are still clinical trials and drug approvals to go.

Domestic pharmaceutical companies usually start with generic drugs, and it is extremely rare for companies like Kechuang Bio to start directly with innovative drugs.

They are a typical example of someone who is not short of money.

Li Wanqing replied, "We are still in the process of screening compounds, and there haven't been many changes yet."

As the director of the Lion City R&D Center, Li Wanqing had attended the annual meeting of Kechuang Biotechnology in Suzhou and met some researchers from other R&D centers.

Whether from the internal company forum, researchers' private social media posts, or casual conversations, it seems that Sci-Tech Biotech has not made much progress in innovative drug development.

Among the various business segments of Kechuang Bio, brain-computer interfaces and endorphins are the main sources of profit.

In the area of ​​innovative drugs, we only see the input but not the output. It's normal for the executives, who are all industry insiders in the biopharmaceutical field, to know this.

However, the person in charge will be anxious. With such a large investment and no output for so long, their voice and status within the company will inevitably be low.

If there are any breakthroughs in research and development, whether it's to increase influence or to gain more attention and support, it will definitely be widely publicized.

Li Wanqing hasn't heard anything since then; his colleagues in the innovative drug division are like they've entered silent mode, so he knows there's obviously no breakthrough progress.

This part will definitely be included in the weekly work summary for Zheng Li, but since there is no progress in innovative drugs, it will only take up one sentence in the work report at most.

Zheng Li doesn't really know the true situation of innovative drugs either.

After listening to Li Wanqing's answer, he said, "Innovative drugs do require a relatively large investment and are a long-term investment."

“Back when I was working on endorphins, they weren’t exactly innovative drugs; they were generic drugs.”

Li Wanqing flattered, "Endorphins were discovered by scientists in the last century, but no one has figured out how to manufacture them, let alone how to produce them on a large scale."

"Your research findings are no less challenging than any innovative drug."

After its launch, the revenue and profits of endorphins were comparable to those of any multinational pharmaceutical giant's flagship product.

It can be said to be the foundation of scientific and technological innovation.

Even with an investment of billions of US dollars, innovative drugs may not necessarily develop into a next blockbuster product with similar effects.

Take Pfizer as an example. Before sildenafil was introduced, Pfizer lagged far behind Merck in both revenue and profit.

After sildenafil was introduced, Pfizer quickly surpassed Merck with just this one drug. Of course, Merck has made a comeback in the last two years.

However, sildenafil elevated Pfizer to a whole new level.

Of course, Kechuang Biotech and Pfizer are different. Since the launch of brain-computer interface phones, Kechuang Biotech has been viewed by the outside world as a diversified company, not just limited to the field of biomedicine.

Zheng Li sorted out his thoughts. His hope for Kechuang Bio was to expand its scale, improve its R&D capabilities, and ensure that it could implement his R&D ideas effectively when necessary.

This chapter is not finished yet. Please click on the next page to continue reading the exciting content!